IMPROVING ACCESS TO
ESSENTIAL MEDICINES FOR
MENTAL, NEUROLOGICAL,
AND SUBSTANCE USE
DISORDERS IN
SUB-SAHARAN AFRICA
WORKSHOP SUMMARY
Forum on Neuroscience and
Nervous System Disorders
Board on Health Sciences Policy
Board on Global Health
Diana E. Pankevich, Sheena M. Posey Norris,
Theresa M. Wizemann, and Bruce M. Altevogt,
Rapporteurs
INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES
THE NATIONAL ACADEMIES PRESS
Washington, D.C.
THE NATIONAL ACADEMIES PRESS • 500 Fifth Street, NW • Washington, DC 20001
NOTICE: The workshop that is the subject of this workshop summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.
This project was supported by contracts between the National Academy of Sciences and the Alzheimer’s Association; CeNeRx Biopharma; the Department of Health and Human Services’ National Institutes of Health (NIH, Contract No. HHSN26300026 [Under Master Base # DHHS-10001018]) through the National Eye Institute, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (101-D27015); Eli Lilly and Company; Fast Forward, LLC; Foundation for the National Institutes of Health; GE Healthcare, Inc. (2580261187); GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck Research Laboratories; The Michael J. Fox Foundation for Parkinson’s Research; the National Science Foundation (Contract No. OIA-0753701); One Mind for Research; Pfizer Inc.; the Society for Neuroscience; and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project.
International Standard Book Number-13: 978-0-309-28810-1
International Standard Book Number-10: 0-309-28810-X
Additional copies of this report are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.
For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.
Copyright 2014 by the National Academy of Sciences. All rights reserved.
Printed in the United States of America
The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.
Suggested citation: IOM (Institute of Medicine). 2014. Improving access to essential medicines for mental, neurological, and substance use disorders in sub-Saharan Africa: Workshop summary. Washington, DC: The National Academies Press.
THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine
The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.
The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. C. D. Mote, Jr., is president of the National Academy of Engineering.
The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Victor J. Dzau is president of the Institute of Medicine.
The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. C. D. Mote, Jr., are chair and vice chair, respectively, of the National Research Council.
PLANNING COMMITTEE ON IMPROVING ACCESS TO ESSENTIAL MEDICINES FOR MENTAL, NEUROLOGICAL, AND SUBSTANCE USE DISORDERS IN SUB-SAHARAN AFRICA1
STEVEN HYMAN (Chair), The Broad Institute
DAN CHISHOLM, World Health Organization
PAMELA COLLINS, National Institute of Mental Health
BONFACE FUNDAFUNDA, Medical Stores Limited
FRANCES JENSEN, University of Pennsylvania School of Medicine
RICHARD LAING, Boston University School of Public Health
ALAN LESHNER, American Association for the Advancement of Science
HUSSEINI MANJI, Johnson & Johnson Pharmaceutical Research and Development, LLC
DAVID MICHELSON, Merck Research Laboratories
EVA OMBAKA, Saint John’s University of Tanzania
ATUL PANDE, GlaxoSmithKline, Inc.
TEDLA WOLDE-GIORGIS, Ministry of Health, Ethiopia
IOM Staff
BRUCE M. ALTEVOGT, Project Director
DIANA E. PANKEVICH, Program Officer
SHEENA M. POSEY NORRIS, Research Associate
RACHEL J. KIRKLAND, Senior Program Assistant (until April 2014)
______________
1Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS1
STEVEN HYMAN (Chair), The Broad Institute
SUSAN AMARA, Society for Neuroscience
MARC BARLOW, GE Healthcare, Inc.
MARK BEAR, Massachusetts Institute of Technology
KATJA BROSE, Cell Press
DANIEL BURCH, Pharmaceutical Product Development, LLC
MARIA CARRILLO, Alzheimer’s Association
C. THOMAS CASKEY, Baylor College of Medicine
TIMOTHY COETZEE, Fast Forward, LLC
EMMELINE EDWARDS, National Center for Complementary and Alternative Medicine
MARTHA FARAH, University of Pennsylvania
RICHARD FRANK, GE Healthcare, Inc.
DANIEL GESCHWIND, University of California, Los Angeles
HANK GREELY, Stanford University
MYRON GUTMANN, National Science Foundation
MAGALI HAAS, Orion Bionetworks
RICHARD HODES, National Institute on Aging
STUART HOFFMAN, U.S. Department of Veterans Affairs
THOMAS INSEL, National Institute of Mental Health
PHILLIP IREDALE, Pfizer Global Research and Development
DANIEL JAVITT, Nathan S. Kline Institute for Psychiatric Research
FRANCES JENSEN, University of Pennsylvania School of Medicine
STORY LANDIS, National Institute of Neurological Disorders and Stroke
ALAN LESHNER, American Association for the Advancement of Science
HUSSEINI MANJI, Johnson & Johnson Pharmaceutical Research and Development, LLC
DAVID MICHELSON, Merck Research Laboratories
RICHARD MOHS, Lilly Research Laboratories
JONATHAN MORENO, University of Pennsylvania
ATUL PANDE, GlaxoSmithKline, Inc.
______________
1Institute of Medicine forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
STEVEN PAUL, Weill Cornell Medical College
TODD SHERER, The Michael J. Fox Foundation for Parkinson’s Research
PAUL SIEVING, National Eye Institute
MARC TESSIER-LEVIGNE, Rockefeller University
WILLIAM THIES, Alzheimer’s Association
JOANNE TORNOW, National Science Foundation
NORA VOLKOW, National Institute on Drug Abuse
KENNETH WARREN, National Institute on Alcohol Abuse and Alcoholism
DAVID WHOLLEY, Foundation for the National Institutes of Health
JOHN WILLIAMS, Wellcome Trust
STEVIN ZORN, Lundbeck Research USA
CHARLES ZORUMSKI, Washington University School of Medicine
IOM Staff
BRUCE M. ALTEVOGT, Forum Director
DIANA E. PANKEVICH, Program Officer
SHEENA M. POSEY NORRIS, Research Associate
RACHEL J. KIRKLAND, Senior Program Assistant (until April 2014)
ANDREW M. POPE, Director, Board on Health Sciences Policy
BOARD ON GLOBAL HEALTH
THOMAS C. QUINN (Chair), National Institute of Allergies and Infectious Diseases, National Institutes of Health; and Johns Hopkins University School of Medicine
JO IVEY BOUFFORD, New York Academy of Medicine
CLAIRE V. BROOME, Department of Global Health, Rollins School of Public Health, Emory University
JACQUELYN C. CAMPBELL, Johns Hopkins University School of Nursing
THOMAS J. COATES, University of California, Los Angeles, Program in Global Health and Division of Infectious Diseases
GARY DARMSTADT, Global Development Division, The Bill & Melinda Gates Foundation
VALENTIN FUSTER, Wiener Cardiovascular Institute, Kravis Cardiovascular Health Center; and Mount Sinai School of Medicine, Mount Sinai Medical Center
JACOB A. GAYLE, Community Affairs, Medtronic Foundation
GLENDA E. GRAY, South African Medical Research Council
STEPHEN W. HARGARTEN, Global Health Program, Medical College of Wisconsin
PETER J. HOTEZ, Texas Children’s Hospital; Sabin Vaccine Institute; Texas Children’s Center for Vaccine Development; and National School of Tropical Medicine, Baylor College of Medicine
CLARION JOHNSON, Private Consultant
FITZHUGH MULLAN, Department of Health Policy, George Washington University
GUY H. PALMER, School for Global Animal Health, Washington State University
IOM Staff
GILLIAN BUCKLEY, Program Officer
PATRICK W. KELLEY, Senior Board Director, Board on Global Health
Reviewers
This workshop summary has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published workshop summary as sound as possible and to ensure that the workshop summary meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this workshop summary:
Albert Akpalu, Korle Bu Teaching Hospital
François Bompart, Sanofi
Marcelo Cruz, Padre Carollo Hospital
Hans Hogerzeil, Groningen University
Prashant Yadav, University of Michigan
Although the reviewers listed above have provided many constructive comments and suggestions, they did not see the final draft of the workshop summary before its release. The review of this workshop summary was overseen by Brian Strom, Rutgers, The State University of New Jersey. Appointed by the Institute of Medicine, he was responsible for making certain that an independent examination of this workshop summary was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this workshop summary rests entirely with the rapporteurs and the institution.
